Key opinion leaders explore the impact of newly available biosimilars and generic biologics for managing multiple sclerosis (MS), discussing how these developments have altered patient access to treatments and the implications for the future of the MS treatment landscape.
The vice president of scientific engagement at Alzheimer's Association talked about recent studies that highlight the progress made in blood biomarker tests for diagnosis, the impact of air pollution on brain health, and promising treatments for Alzheimer disease. [WATCH TIME: 8 minutes]
John England, MD, and Lisa Merlin, MD, commented on the significant changes to neurology over the years and how education aligns with the latest in treatments advancements and understanding of neurological disorders.
The assistant professor at Duke University School of Nursing talked about a project aimed at developing a music-based mobile app to improve sleep for individuals with dementia and their caregivers. [WATCH TIME: 5 minutes]
An expert in NF1-PN describes their approach to treatment decision-making for adolescents versus adults, and identifies key barriers and unmet needs in the transition from adolescent to adult care for patients with this condition.
The co-founder and chief science officer at Longeveron provided commentary on the therapeutic potential of Lomecel-B, a living cell product in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]
The duo provided insight on a number of key sessions clinicians and neurology educators should attend at the upcoming AUPN Annual Meeting.
The professor of neuroscience at Imperial College London talked about results from a study assessing a glucagon-like peptide-1 analogue, liraglutide, in patients with Alzheimer disease. [WATCH TIME: 5 minutes]
Panelists John England, MD, FAAN, and Lisa Merlin, MD, discuss the main objectives of the upcoming AUPN Annual Meeting, set to take place September 14th in Orlando, Florida.
The chief medical officer at Eisai provided context towards the ongoing initiatives to further the efficacy and safety profile of lecanemab, an FDA-approved treatment for early Alzheimer disease. [WATCH TIME: 3 minutes]
A duo of experts talked about the association of long-term exposure to fine particulate matter from wildfires and the increased risk of dementia among older adults. [WATCH TIME: 7 minutes]
The director of the Brain Health Observatory at the University of Southern California talked about integrating blood tests into primary care to better triage patients with Alzheimer disease, reduce unnecessary referrals, and shorten appointment wait times. [WATCH TIME: 7 minutes]
Neurology News Network. for the week ending July 27, 2024. [WATCH TIME: 4 minutes]
The panel identifies and discusses the unmet needs of patients with mild to moderate multiple sclerosis (MS), highlighting areas where current treatment options and management strategies fall short in addressing the unique challenges faced by this patient population.
Medical experts debate the concept of benign multiple sclerosis (MS), questioning whether this subtype truly exists or if it is a misnomer in the context of the disease's long-term progression and impact on patients.
The president and CEO at Alzheon shared recent insights into neurodegenerative diseases that suggest a single toxic trigger may be responsible for conditions like Alzheimer disease, leading to potential early intervention and treatment strategies. [WATCH TIME: 10 minutes]
A neurofibromatosis specialist explores the complexities encountered in managing NF1-PN, highlighting the distinct challenges that arise when treating patients across different age groups.
The professor of neurology at Stony Brook Medicine talked about the promising potential in ongoing studies assessing BTK inhibitors as treatment for primary progressive multiple sclerosis. [WATCH TIME: 3 minutes]
The assistant professor at Hunter College talked about the approach of localization to prevent misdiagnoses of multiple sclerosis and ensure patients receive appropriate treatment. [WATCH TIME: 3 minutes]
A panel of experts discuss safety concerns with intrathecal baclofen ITB pumps.
A panel of experts discuss how intrathecal baclofen ITB pumps have changed over time.
A panel of experts discuss ITB use in spasticity treatment.
A panel of experts discuss available options for treatment of severe spasticity.
Medical professionals explore the challenges and considerations associated with patients with spinal muscular atrophy (SMA) transitioning to independent living, emphasizing the importance of maintaining continuity of care and addressing potential adherence issues to ensure optimal disease management.
Panelists examine the available real-world data (RWD) on the use of risdiplam in adult patients with spinal muscular atrophy (SMA) from various studies conducted worldwide, discussing its potential efficacy and safety as a treatment option for adult SMA patients.
The president and CEO at Alzheon talked about a novel Alzheimer disease drug that shows promising early results in reducing key biomarkers and stabilizing cognitive function in a challenging patient population. [WATCH TIME: 10 minutes]
The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals discussed how sodium oxybate has evolved over the years and the educational aspects of cardiovascular implications patients and clinicians should be aware of. [WATCH TIME: 3 minutes]
The neuroradiologist at Mayo Clinic discussed the categorization of biomarkers for Alzheimer disease, focusing on core biomarkers specific to the disease and those reflecting related pathologies. [WATCH TIME: 8 minutes]
A duo of experts from Mayo Clinic discussed how recent developments in clinical criteria for diagnosing limbic-predominant amnestic neurodegenerative syndrome allow for more accurate differentiation from Alzheimer disease. [WATCH TIME: 9 minutes]
